2-Deoxy-D-Glucose for COVID-19 Treatment
Author Information
Author(s): Muacevic Alexander, Adler John R, Sandepogu Triven Sagar, Dara Chennakesavulu, Mallamgunta Saranya, Jogi Suneeth, Sree Podila Karuna, Chandrasekhar Jwala, N Vijayalakshmi, Sivakumar Swetha
Primary Institution: Employees' State Insurance Corporation (ESIC) Medical College and Hospital, Sanathnagar, Hyderabad, IND
Hypothesis
Does 2-Deoxy-D-Glucose enhance the efficacy of standard care for moderate to severe COVID-19?
Conclusion
2-DG significantly improves clinical outcomes in moderate to severe COVID-19 patients, reducing recovery time and hospital stay.
Supporting Evidence
- Patients receiving 2-DG showed a mean time to clinical improvement of 5.2 days compared to 7.5 days for SOC alone.
- Adverse events were less frequent in the 2-DG group (6.7%) compared to the SOC group (13.3%).
- Oxygen supplementation needs decreased significantly in the 2-DG group by Day 5.
- Viral clearance rates were higher in the 2-DG group.
- WHO ordinal scores improved significantly in the 2-DG group across multiple intervals.
Takeaway
This study shows that a medicine called 2-DG can help people with serious COVID-19 get better faster and stay in the hospital for less time.
Methodology
Retrospective analysis of 150 patients treated with 2-DG alongside standard care for COVID-19, measuring clinical improvement and other outcomes.
Limitations
Small sample size and single-center design may limit generalizability; study conducted during multiple SARS-CoV-2 variants circulation.
Participant Demographics
Patients aged 18-65 with confirmed COVID-19, including both genders.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website